Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination

The development of a group B streptococcal (GBS) glycoconjugate vaccine and its upcoming evaluation in a phase 3 trial in pregnant women highlight the importance of defining the anticipated impact of GBS vaccination upon the broad spectrum of GBS-related perinatal morbidity and mortality. We present the specific pregnancy-associated and neonatal conditions attributable, at least in part, to GBS in high and lower income countries. We offer a rationale to support our contention that implementation of GBS glycoconjugate immunization during pregnancy will reduce the global burden of GBS-related morbidity and mortality in pregnant women and their infants.

► GBS contributes substantially to maternal pregnancy-associated morbidity. ► GBS contributes substantially to neonatal morbidity and mortality. ► GBS immunization during pregnancy will reduce peripartum morbidity and rates of prematurity and stillbirth. ► GBS immunization during pregnancy will reduce deaths and improve long-term outcomes in neonates and young infants.